Xeris Biopharma Holdings, Inc.
لا صفقات
الأساسيات والإحصائيات
Top segments and regional performance
Last year, the company generated 196.64 M USD, the most of which — 196.64 M USD — came from its top-performing segment, Gvoke, Keveyis and Recorlev, compared to 153.36 M USD the previous year. The greatest contribution came from الولايات المتحدة الأمريكية, which accounted for 203.07 M USD last year, with 163.91 M USD the year before.
حسب المصدر
حسب البلد